Recherche.
Ce que la littérature publiée rapporte sur les composés de notre catalogue — l'essai, le chiffre, la source. Chaque affirmation est attribuée ; rien ici n'est un avis médical ni un protocole d'usage chez l'humain.
SecretagoguesIbutamoren (MK-677): the oral secretagogue with a two-year human trial
Most compounds in this catalog have no human data at all. This one has three randomised trials: a pulse study from 1996, an obesity study from 1998, and a two-year trial in 65 older adults that added fat-free mass without moving visceral fat. The numbers, exactly as published.
30 septembre 2026 · 3 min de lecture
MetabolicLiver support pens: reading the label against the literature
Two multi-ingredient liver pens, opened up component by component. Silymarin has a Cochrane review that reads against it, NAC has a poisoning antidote trial that does not transfer, and the finished blends have no trial at all.
29 septembre 2026 · 5 min de lecture
RepairBPC-157 in tendon research: what the rat studies actually show
Tendon models are the core of the BPC-157 animal literature, and a 2025 systematic review put the field's ratio at 35 preclinical studies to 1 clinical study. This page stays inside that ratio.
28 septembre 2026 · 2 min de lecture
HormonalHCG and enclomiphene: what the fertility trials actually studied
Two compounds, four published studies, and a hard boundary: the literature describes what was measured in enrolled patients — intratesticular testosterone, sperm counts, pregnancies — not a protocol for anyone else. This article stays on the published side of that line.
28 septembre 2026 · 4 min de lecture
GH axisHGH vs peptides: somatropin and the secretagogues, compared on the evidence
One is the hormone itself, approved since the 1980s for defined deficiency states. The others ask the pituitary to release more of it — and have one small trial, one PK study, or a single approval between them. The comparison searchers want has never actually been run.
28 septembre 2026 · 3 min de lecture
HormonalMelanotan 2: three small trials, no approval — and the relative that got one
The entire human literature on Melanotan 2 is three trials in 23 men, run by one Arizona group in the 1990s. Nothing followed for tanning. Its chemical relative bremelanotide became an approved medicine — for one narrow indication that has nothing to do with tanning.
28 septembre 2026 · 3 min de lecture
BlendsOxytocin: the approved hormone inside the OxyPT blend
One half of the OxyPT blend is among the oldest approved peptide drugs in medicine — used in obstetrics since the 1960s. Here is what the labels actually cover, and what they pointedly do not.
28 septembre 2026 · 1 min de lectureSARMsSARMs part 2: the one with trials, and the four with none
Part 1 covered the compounds with phase 2 and phase 3 programmes. The five left — ibutamoren, stenabolic, andarine, S-23, YK-11 — split into one with three real human trials and an ugly safety footnote, and four with no human efficacy data at all. Two of the five are not even SARMs.
28 septembre 2026 · 4 min de lecture
BioregulatorsCartalax and Chonluten: the bioregulators with almost no published record
Same Khavinson school as Thymalin and Epithalon, a fraction of the evidence. One cell-culture study for Chonluten, no readable efficacy study at all for Cartalax — and that asymmetry is the article.
26 septembre 2026 · 2 min de lecture
LongevityEpithalon and the telomere claim: what the Khavinson papers actually report
Telomerase reactivation in a dish, extra passages past the Hayflick limit, longer-lived flies and mice — and no modern human trial. The published Epithalon record, figure by figure.
26 septembre 2026 · 4 min de lecture
PerformanceMyostatin inhibitors: ACE-083 went to phase 2, follistatin-344 never left the lab
One follistatin-based molecule grew muscle in two randomised phase 2 trials and still failed where it mattered. The other has only animal data, a black market, and a retinal case series. The published record, side by side.
26 septembre 2026 · 4 min de lecture
GLP-1Tirzepatide: what SURMOUNT-1 and SURMOUNT-2 actually showed
Two 72-week placebo-controlled trials, 3,477 participants between them — one in obesity without diabetes, one in obesity with type 2 diabetes. The published weight-loss figures, dose by dose, and where the data stop.
26 septembre 2026 · 3 min de lecture
RepairARA-290 (cibinetide): four human trials, and the endpoints they missed
This is one of the very few compounds on the repair shelf with real randomised human data — four published trials, including a 64-subject phase 2b. Read them closely and the nerve-regeneration endpoint separates from placebo while the pain endpoint mostly does not.
4 septembre 2026 · 6 min de lecture
PerformanceExercise mimetics: what AICAR, SLU-PP-332 and 5-Amino-1MQ have actually done, and in what species
One of these three has been given to 3,080 humans — and the trial was stopped for futility. The other two have never been given to a human at all. All three are sold on the same phrase, and the phrase comes from one mouse treadmill experiment in 2008.
4 septembre 2026 · 6 min de lecture
MetabolicTesofensine: a phase 2 result that never became a phase 3 paper
The 2008 Lancet trial is real, and the numbers in it are large. What followed is the part nobody quotes — an Expression of Concern from the journal, no published phase 3 anywhere in the indexed literature, and no approval in the EU or the US.
4 septembre 2026 · 6 min de lecture
LongevityEndurance, GlutaMB and the antioxidant pens: the labels add up, the trials are less flattering
Glutathione, NMN, resveratrol and methylene blue, in two pre-mixed pens. One component has a good human trial, one has four negative ones, and one is present at a dose thousands of times below the trial that reported a benefit. Ingredient by ingredient.
2 septembre 2026 · 5 min de lecture
ProgramsThe four programs: what you are actually buying when you buy one
A program is the manufacturer's own multi-month protocol sold as the set of pens it calls for — priced below the sum of its parts, delivered on one fee. Here is what is in each of the four, and how strong the evidence under each component really is.
2 septembre 2026 · 4 min de lecture
SleepDSIP: named after an effect that later human work could not reproduce
Isolated from rabbit blood in 1977 and named for the EEG rhythm it enhanced. Four small human insomnia studies produced weak or null results, a 2009 anaesthesia study found it reduced delta rhythm, and no gene or receptor has ever been identified.
1 septembre 2026 · 3 min de lecture
MetabolicHGH Fragment 176-191 and AOD9604: a well-built mouse story with a missing human chapter
The idea was elegant — take growth hormone's fat-metabolism domain and leave the growth and insulin effects behind. It worked in obese mice, repeatedly. PubMed indexes 23 papers mentioning AOD9604 and not one randomised human trial.
1 septembre 2026 · 4 min de lecture
GH axisIGF-1 LR3 and PEG MGF: two names, and what is actually published under each
Recombinant IGF-1 is an approved drug with a registry behind it. The LR3 analogue is a cell-culture reagent. PEG MGF has no administration study at all — the human MGF papers measure a gene switching on, not a peptide going in.
1 septembre 2026 · 4 min de lecture
RepairKPV: three amino acids off the end of α-MSH, and where its evidence actually sits
The mechanism is unusually well worked out — KPV enters cells through PepT1, a transporter that is upregulated exactly where gut inflammation is. Every efficacy result is a mouse or a cell line, and the colitis work was oral, not injected.
1 septembre 2026 · 4 min de lecture
HormonalPT-141 (bremelanotide): the melanocortin that got an approval — for one indication only
Two phase 3 trials, an FDA-approved product and a published critique of its own endpoints. This is the rare compound where the human data exists, and where reading it carefully changes what you can claim.
1 septembre 2026 · 3 min de lecture
RepairThe recovery stack: BPC-157 and TB-500, and why they ship in one pen
The most requested pairing in the repair category, in a single pre-filled pen. What each peptide is doing, what the published work actually reports, and why laboratories keep ordering the two together.
27 août 2026 · 4 min de lecture
MetabolicBurnMix and Lipobalance: the metabolic pens for people who want more than one lever
Two multi-pathway fat-loss formulations, opened up compound by compound. What each ingredient is there to do, which ones have human data, which ones do not, and where they sit next to the GLP-1 shelf.
27 août 2026 · 4 min de lectureBuying guideHow to buy research peptides in Europe: the ten-minute checklist
Six checks that separate a serious European peptide supplier from a drop-shipper with a nice logo — and how to run them on any shop, including this one, before you spend anything.
27 août 2026 · 4 min de lecture
OrderingFrom checkout to doorstep: how a peptide order actually moves inside the EU
Same-day processing, tracked delivery in about four days, a plain unbranded box, and one flat fee per order. Here is every step of a European peptide delivery, including what happens when it goes wrong.
27 août 2026 · 4 min de lecture
GH axisIpamorelin and CJC-1295: the GH-axis pairing labs ask for by name
Two doors into the same output, in one pre-filled pen. Why this combination became the default in growth-hormone research, what the human data covers, and the label detail almost every shop gets wrong.
27 août 2026 · 4 min de lecture
LongevityThe longevity pens: CellDetox and Everlong, and what is really inside them
Senolytics, exosomes, NAD+, glutathione, resveratrol — the two most advanced formulations in our catalog, ingredient by ingredient, with the research that supports each one and the research that does not exist yet.
27 août 2026 · 4 min de lecturePaymentsPaying with USDT, USDC or a bank transfer: how checkout works here
Two payment rails, no cards, no third-party checkout script. What each one costs you in time, why the crypto amount has to be exact, and which one to pick if you want the parcel moving today.
27 août 2026 · 4 min de lecture
SkinThe skin shelf: GHK-Cu and Radiance, copper versus copper-free
One peptide with fifty years of literature, one modern complex built without copper, and a third pen aimed at blemish-prone skin. What is in each, which claims are backed, and how to choose between them.
27 août 2026 · 4 min de lecture
Catalog guideFour departments, twelve shelves: a plain map of the catalog
Peptides, performance compounds, SARMs and programs — what each shelf is actually for, which compounds sit on it, and which article to read before you order from it.
27 août 2026 · 3 min de lecture
ManufacturersNordic Peptides, Med Care Pharma, Marvel Nutrition, PharmaRx: who makes what we ship
Four manufacturers, four very different houses. Which one made the box that arrives, what each of them publishes about their own material, and where each is honestly weaker.
27 août 2026 · 3 min de lecture
BlendsBlends: when a combined pen is the right call, and when it costs you the answer
Klow, MitoBoost, Retabolic — three compounds in one pen, at a lower price than buying the parts. Here is the honest trade you are making when you take it.
23 août 2026 · 2 min de lectureSkin & repairGHK-Cu: the copper peptide with fifty years of literature behind it
Isolated from human plasma in 1973, studied continuously since, and one of the few compounds in this catalog where the human evidence is topical, comparative and reasonably old.
23 août 2026 · 2 min de lecture
GH axisGHRP-2, GHRP-6 or ipamorelin: three ghrelin-receptor peptides, three different side profiles
All three hit the same receptor and all three release growth hormone. What separates them is everything else they do on the way — appetite, cortisol, prolactin.
23 août 2026 · 3 min de lectureGLP-1The GLP-1 line, compared: semaglutide, tirzepatide, retatrutide
One receptor, two, or three. Here is the whole line side by side — the trial numbers, the trade-offs and which pen sits where in our catalog.
23 août 2026 · 3 min de lectureQualitéComment lire un certificat d'analyse (et repérer un faux)
Un COA est un document qui porte sur un lot, un jour donné, d'un seul laboratoire. La plupart de ce qui circule comme « testé en laboratoire » sur ce marché ne satisfait pas cette phrase, et ce en au moins deux points.
23 août 2026 · 3 min de lectureHandlingWhy everything in our peptide line ships as a pen, not a vial
Vials are cheaper to buy and cheaper to sell. They are also where the errors live. Here is the measured difference, and why we made the call the way we did.
23 août 2026 · 3 min de lectureGLP-1Rétatrutide 6, 12, 20 ou 30 mg : quel stylo choisir, et pourquoi il en existe quatre
Les quatre dosages ne sont pas quatre produits. Ils correspondent à la façon dont l'essai de phase 2 a été escaladé — et à la quantité de matière qu'un protocole donné consomme réellement.
23 août 2026 · 3 min de lecture
SARMsSARMs: the phase 3 exists, and it missed its endpoints
This class is usually sold with the word 'clinical' attached. There is real clinical work behind it — two phase 3 trials — and knowing what they found is the difference between an informed buyer and a marketed-to one.
23 août 2026 · 3 min de lecture
NeuroSemax and Selank: two Russian peptides with a literature problem
Both are approved medicines in Russia. Both have decades of clinical use behind them. Almost none of that work is readable in English, and that gap is the honest headline.
23 août 2026 · 3 min de lectureHandlingWhat actually degrades a peptide (and why we don't ship on ice)
The cold-chain theatre in this market is mostly theatre. Here is what the manufacturers themselves specify, what really damages a peptide, and the one product in our catalog that is an exception.
23 août 2026 · 3 min de lecture
BioregulatorsThymalin and the Khavinson bioregulators: forty years of data from one institute
The longest human follow-up of any compound in this catalog — 266 elderly patients over six to eight years — and the reason mainstream medicine still has not acted on it.
23 août 2026 · 2 min de lectureRéparationBPC-157 : ce que disent réellement les données
Trente-cinq études précliniques, une seule étude clinique. Ce rapport résume à lui seul le dossier du BPC-157 : un composé doté d'une littérature animale abondante et assez cohérente, mais de presque aucune donnée humaine.
21 août 2026 · 4 min de lectureGLP-1Rétatrutide : ce que montrent réellement les données de phase 2
Un agoniste triple des récepteurs ayant produit les plus fortes réductions de poids publiées à ce jour pour un médicament unique contre l'obésité : 24,2 % à 48 semaines. Voici ce que l'essai a mesuré, et ce qu'il n'a pas mesuré.
21 août 2026 · 4 min de lectureGLP-1Tirzépatide contre sémaglutide : le premier essai comparatif direct
Pendant des années, la comparaison reposait sur des études distinctes, ce qui n'est pas une comparaison. En 2025, les deux molécules ont enfin été confrontées dans un même essai — 751 participants, 72 semaines, un seul protocole.
21 août 2026 · 3 min de lecture
GH axisCJC-1295 and ipamorelin: two mechanisms, one very common confusion
The pairing is the most requested combination in the GH-axis line. It is also the one where the label on the vial and the study people quote are frequently not the same molecule.
19 août 2026 · 3 min de lectureMetabolicMOTS-c: the peptide your mitochondria write themselves
A 16-amino-acid peptide encoded inside mitochondrial DNA, released by exercise, and falling with age. The mechanism is elegant and well documented — in mice.
19 août 2026 · 2 min de lecture
MetabolicNAD+, NMN and nicotinamide: three different molecules, one marketing word
The NAD category is sold as if it were one product. It is not — and the one human randomised trial in the field tested a specific precursor, at a specific dose, in a specific population.
19 août 2026 · 2 min de lectureGLP-1Semaglutide: what the STEP programme showed — and what happened when people stopped
14.9% at 68 weeks made semaglutide famous. The trial extension, which gets far less attention, is the part that explains what the drug actually does.
19 août 2026 · 3 min de lecture
RéparationTB-500 et thymosine β4 : les essais cliniques sont réels, mais il s'agit de collyres
La thymosine β4 a fait l'objet d'essais humains randomisés et contrôlés par placebo, dont un essai de phase 3. Presque aucun de ces travaux ne porte sur le fragment injectable vendu sous le nom de TB-500, et cette différence est au cœur du sujet.
19 août 2026 · 3 min de lecture
GH axisTesamorelin: the one growth hormone peptide with an approval behind it
Of every GHRH-class compound sold as research material, exactly one has been through phase 3 and cleared by the FDA. Here is what that trial measured — and why the indication is narrower than the internet suggests.
19 août 2026 · 3 min de lecture